CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 1.9%

CRISPR Therapeutics AG (NASDAQ:CRSP) shot up 1.9% during trading on Tuesday . The company traded as high as $72.44 and last traded at $72.40. 223,278 shares changed hands during mid-day trading, a decline of 89% from the average session volume of 1,971,836 shares. The stock had previously closed at $71.08.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on CRSP. Morgan Stanley lifted their target price on shares of CRISPR Therapeutics from $46.00 to $48.00 and gave the company an “underweight” rating in a report on Monday, February 26th. Royal Bank of Canada upped their price objective on CRISPR Therapeutics from $57.00 to $66.00 and gave the stock a “sector perform” rating in a research report on Thursday, February 22nd. Chardan Capital increased their target price on shares of CRISPR Therapeutics from $110.00 to $112.00 and gave the company a “buy” rating in a research report on Thursday, February 22nd. Wells Fargo & Company raised their price target on CRISPR Therapeutics from $55.00 to $70.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 22nd. Finally, JMP Securities lifted their price objective on shares of CRISPR Therapeutics from $74.00 to $80.00 and gave the company a “market outperform” rating in a research note on Monday, December 11th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, CRISPR Therapeutics has a consensus rating of “Hold” and a consensus price target of $74.75.

CRISPR Therapeutics Stock Down 1.1 %

The firm’s 50 day moving average is $73.75 and its two-hundred day moving average is $61.71.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.95. The firm had revenue of $201.20 million for the quarter, compared to the consensus estimate of $148.72 million. CRISPR Therapeutics had a negative return on equity of 8.09% and a negative net margin of 240.84%. The firm’s revenue for the quarter was up 3253.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.41) earnings per share. Equities analysts expect that CRISPR Therapeutics AG will post -6.24 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 50,000 shares of the firm’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $60.51, for a total value of $3,025,500.00. Following the transaction, the chief executive officer now directly owns 187,377 shares of the company’s stock, valued at $11,338,182.27. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 50,000 shares of the stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $60.51, for a total value of $3,025,500.00. Following the completion of the sale, the chief executive officer now owns 187,377 shares of the company’s stock, valued at $11,338,182.27. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel James R. Kasinger sold 1,913 shares of the business’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total transaction of $152,408.71. Following the transaction, the general counsel now directly owns 57,371 shares in the company, valued at $4,570,747.57. The disclosure for this sale can be found here. Insiders sold a total of 134,410 shares of company stock worth $9,234,677 over the last ninety days. 4.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CRSP. Fairfield Bush & CO. bought a new stake in shares of CRISPR Therapeutics in the first quarter worth $90,000. Bank of New York Mellon Corp increased its position in shares of CRISPR Therapeutics by 40.7% in the 1st quarter. Bank of New York Mellon Corp now owns 91,062 shares of the company’s stock worth $5,716,000 after purchasing an additional 26,358 shares during the last quarter. US Bancorp DE raised its stake in shares of CRISPR Therapeutics by 10.0% in the 1st quarter. US Bancorp DE now owns 9,526 shares of the company’s stock valued at $598,000 after purchasing an additional 866 shares in the last quarter. BlackRock Inc. lifted its position in shares of CRISPR Therapeutics by 79.2% during the first quarter. BlackRock Inc. now owns 2,278,774 shares of the company’s stock worth $143,038,000 after purchasing an additional 1,007,246 shares during the last quarter. Finally, Cibc World Market Inc. grew its stake in CRISPR Therapeutics by 49.3% in the first quarter. Cibc World Market Inc. now owns 8,354 shares of the company’s stock worth $524,000 after purchasing an additional 2,760 shares in the last quarter. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.